Reports

Ideas That Generate Results

The Asia-Pacific region is emerging as the fastest growing pharmaceutical industry in the global pharmaceutical arena. In the recent years, the demand for healthcare services has risen among the region’s populations. According to our new research report, the low operating costs and skilled manpower continue to attract pharmaceutical companies towards Asia Pacific, which is now emerging as a powerhouse of pharmaceutical Research & Development (R&D). The future of the industry in the region remains bright, and is projected to grow at a compound annual rate of around 10% during 2012-2015.

The report, “Asia Pacific Pharma Sector Analysis”, finds that the market growth will mainly be driven by factors, like changing regulatory environment, increasing disposable incomes, rising prevalence of lifestyle diseases, and significant developments in the field of contract manufacturing, particularly in APIs. On studying the pharmaceutical market in each country, we observed that mature markets such as Japan and Australia are experiencing slower growth rates, while emerging as new market leaders, China and India are enjoying investments by foreign pharmaceutical companies. South Korea and New Zealand are relatively small markets, with the growth limited by the size of these island nations. We have also studied the market scenario in Indonesia, Thailand, the Philippines, Malaysia and Vietnam.

We also found out why the Asia-Pacific region is emerging as a new destination for the generic drugs industry. As per our findings, the western countries face the issue of poorly defined regulatory pathways, and a few Asian countries are well positioned to benefit from these changes, attracting huge investments by generic companies. The OTC sector in the region has also been expanding rapidly. The study of other emerging trends revealed that the growing market for vaccines and medical tourism is giving new dimension to the region’s pharmaceutical industry. Though Asia-Pacific is emerging as a right place for the drug-related research, the region lacks IPR regime. The report provides in-depth information about regulatory environment and key market players in each country. This way, our research work aims at presenting a fair picture of the industry to clients.